Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
189.12B
Market cap189.12B
Price-Earnings ratio
24.82
Price-Earnings ratio24.82
Dividend yield
2.74%
Dividend yield2.74%
Average volume
2.87M
Average volume2.87M
High today
$355.67
High today$355.67
Low today
$349.94
Low today$349.94
Open price
$355.67
Open price$355.67
Volume
792.86K
Volume792.86K
52 Week high
$391.29
52 Week high$391.29
52 Week low
$261.43
52 Week low$261.43

Stock Snapshot

Amgen(AMGN) stock is priced at $350.82, giving the company a market capitalization of 189.12B. It carries a P/E multiple of 24.82 and pays a dividend yield of 2.7%.

As of 2026-03-27, Amgen(AMGN) stock has fluctuated between $349.94 and $355.67. The current price stands at $350.82, placing the stock +0.3% above today's low and -1.4% off the high.

Amgen(AMGN) shares are trading with a volume of 792.86K, against a daily average of 2.87M.

During the past year, Amgen(AMGN) stock moved between $261.43 at its lowest and $391.29 at its peak.

During the past year, Amgen(AMGN) stock moved between $261.43 at its lowest and $391.29 at its peak.

AMGN News

Simply Wall St 9h
Assessing Amgen Valuation As Shares Show Mixed Short And Long Term Returns

Advertisement What Amgen’s Recent Share Moves Signal for Investors Amgen (AMGN) has seen mixed recent returns, with gains over the past year but a decline ove...

Assessing Amgen Valuation As Shares Show Mixed Short And Long Term Returns
TipRanks 2d
Amgen’s Rocatinlimab Trial Completion Signals Next Phase for Atopic Dermatitis Strategy

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has reported a key update on its Phase 3 ROCKET-Outpost study, which lo...

Analyst ratings

53%

of 38 ratings
Buy
39.5%
Hold
52.6%
Sell
7.9%

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.